Stock Analiz

PAVmed Inc. PAVM

Medical/Dental Instruments · IPO 2016 · data as of November 13, 2026

$1.63Market cap $13M
Open the interactive analysis →

PAVmed Inc. (PAVM) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to September 30, 2026 it had revenue of $148000 and net income of -$18M, a net margin of -12472.3%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -140%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.

About PAVmed

PAVmed is listed in the US and classified in medical/dental instruments, IPO year 2016. It was profitable in 2 of the last 10 years in our data. Its share count rose by 239% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S88.1
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-40.2%
Shareholder yield0.0%
Intrinsic value vs. price−97%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-12079.8%
ROIC (5-yr avg.)-140.2%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$148000——$2M$377000$500000—————
Net income-$18M$401000$40M-$64M-$89M-$50M-$34M-$16M-$18M-$10M-$6M
Free cash flow—-$5M-$34M-$52M-$73M-$42M-$22M-$13M-$9M-$7M-$4M
EPS (diluted)$-7.78$-5.63$14.90$-275.18$-451.52$-19.53$-21.63$-16.22$-24.33$-21.33$-13.22
Net margin-12472.3%——-2567.0%-23602.9%-10069.4%—————
ROIC—-49.5%-174.5%—-267.0%-69.7%-840.0%————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $36.50, 2139% above the current price; targets range from $16.00 to $57.00; the consensus rating is “none”; expected EPS is $-2.33 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is PAVmed stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does PAVmed pay a dividend?

Not currently.

Is PAVmed a good stock to buy?

We do not give buy or sell advice. PAVmed scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.